-
Je něco špatně v tomto záznamu ?
Monitoring of radiologic disease activity by serum neurofilaments in MS
T. Uher, S. Schaedelin, B. Srpova, C. Barro, N. Bergsland, M. Dwyer, M. Tyblova, K. Vodehnalova, P. Benkert, J. Oechtering, D. Leppert, Y. Naegelin, J. Krasensky, M. Vaneckova, E. Kubala Havrdova, L. Kappos, R. Zivadinov, D. Horakova, J. Kuhle,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2014
Free Medical Journals
od 2014
Freely Accessible Science Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014 do 2020
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2014
- MeSH
- dospělí MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mladý dospělý MeSH
- neurofilamentové proteiny krev MeSH
- progrese nemoci * MeSH
- relabující-remitující roztroušená skleróza krev diagnóza patologie MeSH
- senzitivita a specificita MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
OBJECTIVE: To determine whether serum neurofilament light chain (sNfL) levels are associated with recent MRI activity in patients with relapsing-remitting MS (RRMS). METHODS: This observational study included 163 patients (405 samples) with early RRMS from the Study of Early interferon-beta1a (IFN-β1a) Treatment (SET) cohort and 179 patients (664 samples) with more advanced RRMS from the Genome-Wide Association Study of Multiple Sclerosis (GeneMSA) cohort. Based on annual brain MRI, we assessed the ability of sNfL cutoffs to reflect the presence of combined unique active lesions, defined as new/enlarging lesion compared with MRI in the preceding year or contrast-enhancing lesion. The probability of active MRI lesions among patients with different sNfL levels was estimated with generalized estimating equations models. RESULTS: From the sNfL samples ≥90th percentile, 81.6% of the SET (OR = 3.4, 95% CI = 1.8-6.4) and 48.9% of the GeneMSA cohort samples (OR = 2.6, 95% CI = 1.7-3.9) was associated with radiological disease activity on MRI. The sNfL level between the 10th and 30th percentile was reflective of negligible MRI activity: 1.4% (SET) and 6.5% (GeneMSA) of patients developed ≥3 active lesions, 5.8% (SET) and 6.5% (GeneMSA) developed ≥2 active lesions, and 34.8% (SET) and 11.8% (GeneMSA) showed ≥1 active lesion on brain MRI. The sNfL level <10th percentile was associated with even lower MRI activity. Similar results were found in a subgroup of clinically stable patients. CONCLUSIONS: Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of recent radiologic disease activity during the preceding year. This result suggests that in future, sNfL assessment may substitute the need for annual brain MRI monitoring in considerable number (23.1%-36.4%) of visits in clinically stable patients.
Clinical Trial Unit Department of Clinical Research University Hospital Basel University of Basel
Department of Neurology The Royal Melbourne Hospital Victoria Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026727
- 003
- CZ-PrNML
- 005
- 20240903114739.0
- 007
- ta
- 008
- 211013s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1212/NXI.0000000000000714 $2 doi
- 035 __
- $a (PubMed)32273481
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Uher, Tomas $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
- 245 10
- $a Monitoring of radiologic disease activity by serum neurofilaments in MS / $c T. Uher, S. Schaedelin, B. Srpova, C. Barro, N. Bergsland, M. Dwyer, M. Tyblova, K. Vodehnalova, P. Benkert, J. Oechtering, D. Leppert, Y. Naegelin, J. Krasensky, M. Vaneckova, E. Kubala Havrdova, L. Kappos, R. Zivadinov, D. Horakova, J. Kuhle, T. Kalincik
- 520 9_
- $a OBJECTIVE: To determine whether serum neurofilament light chain (sNfL) levels are associated with recent MRI activity in patients with relapsing-remitting MS (RRMS). METHODS: This observational study included 163 patients (405 samples) with early RRMS from the Study of Early interferon-beta1a (IFN-β1a) Treatment (SET) cohort and 179 patients (664 samples) with more advanced RRMS from the Genome-Wide Association Study of Multiple Sclerosis (GeneMSA) cohort. Based on annual brain MRI, we assessed the ability of sNfL cutoffs to reflect the presence of combined unique active lesions, defined as new/enlarging lesion compared with MRI in the preceding year or contrast-enhancing lesion. The probability of active MRI lesions among patients with different sNfL levels was estimated with generalized estimating equations models. RESULTS: From the sNfL samples ≥90th percentile, 81.6% of the SET (OR = 3.4, 95% CI = 1.8-6.4) and 48.9% of the GeneMSA cohort samples (OR = 2.6, 95% CI = 1.7-3.9) was associated with radiological disease activity on MRI. The sNfL level between the 10th and 30th percentile was reflective of negligible MRI activity: 1.4% (SET) and 6.5% (GeneMSA) of patients developed ≥3 active lesions, 5.8% (SET) and 6.5% (GeneMSA) developed ≥2 active lesions, and 34.8% (SET) and 11.8% (GeneMSA) showed ≥1 active lesion on brain MRI. The sNfL level <10th percentile was associated with even lower MRI activity. Similar results were found in a subgroup of clinically stable patients. CONCLUSIONS: Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of recent radiologic disease activity during the preceding year. This result suggests that in future, sNfL assessment may substitute the need for annual brain MRI monitoring in considerable number (23.1%-36.4%) of visits in clinically stable patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kohortové studie $7 D015331
- 650 12
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a relabující-remitující roztroušená skleróza $x krev $x diagnóza $x patologie $7 D020529
- 650 _2
- $a neurofilamentové proteiny $x krev $7 D016900
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Schaedelin, Sabine $u Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel
- 700 1_
- $a Srpová, Barbora $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic $7 xx0321726
- 700 1_
- $a Barro, Christian $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
- 700 1_
- $a Bergsland, Niels $u Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, University at Buffalo, State University of New York, Buffalo
- 700 1_
- $a Dwyer, Michael $u Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, University at Buffalo, State University of New York, Buffalo
- 700 1_
- $a Tyblova, Michaela $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Vodehnalova, Karolina $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Benkert, Pascal $u Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel
- 700 1_
- $a Oechtering, Johanna $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
- 700 1_
- $a Leppert, David $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
- 700 1_
- $a Naegelin, Yvonne $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
- 700 1_
- $a Krasensky, Jan $u Department of Radiology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Vaneckova, Manuela $u Department of Radiology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Kubala Havrdova, Eva $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Kappos, Ludwig $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
- 700 1_
- $a Zivadinov, Robert $u Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York, NY
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Kuhle, Jens $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
- 700 1_
- $a Kalincik, Tomas $u Department of Neurology, The Royal Melbourne Hospital, Victoria, Australia
- 773 0_
- $w MED00186373 $t Neurology® neuroimmunology & neuroinflammation $x 2332-7812 $g Roč. 7, č. 4 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32273481 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20240903114736 $b ABA008
- 999 __
- $a ok $b bmc $g 1715463 $s 1147234
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 7 $c 4 $e 20200409 $i 2332-7812 $m Neurology® neuroimmunology & neuroinflammation $n Neurol Neuroimmunol Neuroinflamm $x MED00186373
- LZP __
- $a Pubmed-20211013